Rajiv Radhakrishnan, MBBS, MD

  • 10Articles
  • 95.1KReads
  • 2013–2024Active
  • 23Collaborators
  • 156Citations

About

Rajiv Radhakrishnan, MBBS, MD, is affiliated with the Yale Depression Research Program in the Department of Psychiatry at the Yale School of Medicine and the Yale Psychiatric Hospital in New Haven, Connecticut. Since 2013, Radhakrishnan has contributed to Psychiatrist.com on topics including addiction, bipolar disorder, psychedelics, psychopharmacology, Alzheimer disease, complementary and alternative medicine, depression, and schizophrenia/schizoaffective disorders. Frequent collaborators include Avinash Hosanagar, Deepak Cyril D' Souza, Joseph Cusimano, Samuel T. Wilkinson, and Brian Pittman.

Publications

JCP
Ketamine/Esketamine in Bipolar Depression in a Clinical Setting
Original Research

Ketamine/Esketamine in Bipolar Depression in a Clinical Setting

October 2, 2024

In a small sample of patients with bipolar depression treated with ketamine/esketamine, no evidence of mania or hypomania was seen during acute treatment.
, , , et al
JCP
Impact of SUD on COVID-19 Outcomes
Original Research

Impact of SUD on COVID-19 Outcomes

August 29, 2022

Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
, , , et al
JCP
ASCP Corner

Psychedelics and Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects

February 23, 2021

In addition to altering one’s perception of reality, psychedelics may be useful for treating certain psychiatric disorders. This brief review looks at the mechanisms behind their effects.
, ,
JCP
ASCP Corner

Psychedelics and Treatment of Psychiatric Disorders, Part 2: Review of the Evidence

February 23, 2021

Could psychedelics such as psilocybin and LSD be useful in treating MDD or other psychiatric disorders? This brief review looks at the evidence.
, ,
JCP
Original Research

Antipsychotics for Homeless and Unstably Housed Veterans

December 8, 2020

Many homeless and unstably housed (HUH) adults have severe mental illness managed with antipsychotic medications. This study examined antipsychotic medication use and correlates of antipsychotic medication prescriptions among HUH...
, ,
PCC
Original Research

Elevated Unconjugated Bilirubin in Schizophrenia

July 25, 2019

Could serum unconjugated bilirubin be a potential marker for schizophrenia? This study compared levels of patients with schizophrenia to those with bipolar disorder. Read on to find out more.
, , , et al
JCP
ASCP Corner

Medical Marijuana: What Physicians Need to Know

May 7, 2019

As of March 2019, "medical marijuana" has been approved in 33 states; however, these products are not FDA-regulated. This article summarizes the evidence for marijuana in psychiatric indications, as...
, ,
JCP
Article

Medical Marijuana for Psychiatric Indications

August 24, 2016

Too much of a good thing? As of June 2016, marijuana was legal for medical use in 25 states in the US. Learn what the authors discovered during their...
, ,
JCP
Original Research

Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission

June 27, 2014

, , , et al
PCC
Letter to the Editor

A Case of Amelioration of Venlafaxine-Discontinuation "Brain Shivers" With Atomoxetine

March 21, 2013

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe